94 related articles for article (PubMed ID: 17442286)
1. Analysis of vaccine's schedules using models.
Pappalardo F; Motta S; Lollini PL; Mastriani E
Cell Immunol; 2006 Dec; 244(2):137-40. PubMed ID: 17442286
[TBL] [Abstract][Full Text] [Related]
2. Modeling and simulation of cancer immunoprevention vaccine.
Pappalardo F; Lollini PL; Castiglione F; Motta S
Bioinformatics; 2005 Jun; 21(12):2891-7. PubMed ID: 15817697
[TBL] [Abstract][Full Text] [Related]
3. Searching of optimal vaccination schedules: application of genetic algorithms to approach the problem in cancer immunoprevention.
Pennisi MA; Pappalardo F; Zhang P; Motta S
IEEE Eng Med Biol Mag; 2009; 28(4):67-72. PubMed ID: 19622427
[No Abstract] [Full Text] [Related]
4. Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice.
Sas S; Chan T; Sami A; El-Gayed A; Xiang J
Cancer Gene Ther; 2008 Oct; 15(10):655-66. PubMed ID: 18421311
[TBL] [Abstract][Full Text] [Related]
5. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
[TBL] [Abstract][Full Text] [Related]
6. Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag.
Felicetti P; Mennecozzi M; Barucca A; Montgomery S; Orlandi F; Manova K; Houghton AN; Gregor PD; Concetti A; Venanzi FM
Cytotherapy; 2007; 9(1):23-34. PubMed ID: 18236207
[TBL] [Abstract][Full Text] [Related]
7. Antimetastatic activity of a preventive cancer vaccine.
Nanni P; Nicoletti G; Palladini A; Croci S; Murgo A; Antognoli A; Landuzzi L; Fabbi M; Ferrini S; Musiani P; Iezzi M; De Giovanni C; Lollini PL
Cancer Res; 2007 Nov; 67(22):11037-44. PubMed ID: 18006850
[TBL] [Abstract][Full Text] [Related]
8. Immunoprevention of cancer: time to reconsider timing of vaccination against cancer.
Spisek R
Expert Rev Anticancer Ther; 2006 Dec; 6(12):1689-91. PubMed ID: 17181481
[No Abstract] [Full Text] [Related]
9. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
[TBL] [Abstract][Full Text] [Related]
10. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.
Mortara L; Frangione V; Castellani P; De Lerma Barbaro A; Accolla RS
Int Immunol; 2009 Jun; 21(6):655-65. PubMed ID: 19395374
[TBL] [Abstract][Full Text] [Related]
11. In vivo responses to vaccination with Mage-b, GM-CSF and thioglycollate in a highly metastatic mouse breast tumor model, 4T1.
Gravekamp C; Leal B; Denny A; Bahar R; Lampkin S; Castro F; Kim SH; Moore D; Reddick R
Cancer Immunol Immunother; 2008 Jul; 57(7):1067-77. PubMed ID: 18094967
[TBL] [Abstract][Full Text] [Related]
12. An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models.
Dharmapuri S; Aurisicchio L; Neuner P; Verdirame M; Ciliberto G; La Monica N
Cancer Gene Ther; 2009 May; 16(5):462-72. PubMed ID: 18989354
[TBL] [Abstract][Full Text] [Related]
13. A novel murine model of allogeneic vaccination against prostate cancer.
Labarthe MC; Theocharous P; Russell N; Todryk S; Bangma C; Thraves P; Dalgleish AG; Whelan MA
Cancer Immunol Immunother; 2008 Apr; 57(4):453-65. PubMed ID: 17805533
[TBL] [Abstract][Full Text] [Related]
14. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer.
Mennuni C; Ugel S; Mori F; Cipriani B; Iezzi M; Pannellini T; Lazzaro D; Ciliberto G; La Monica N; Zanovello P; Bronte V; Scarselli E
Cancer Res; 2008 Dec; 68(23):9865-74. PubMed ID: 19047167
[TBL] [Abstract][Full Text] [Related]
15. Discovery of cancer vaccination protocols with a genetic algorithm driving an agent based simulator.
Lollini PL; Motta S; Pappalardo F
BMC Bioinformatics; 2006 Jul; 7():352. PubMed ID: 16857043
[TBL] [Abstract][Full Text] [Related]
16. Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer.
Williams BB; Wall M; Miao RY; Williams B; Bertoncello I; Kershaw MH; Mantamadiotis T; Haber M; Norris MD; Gautam A; Darcy PK; Ramsay RG
Cancer Immunol Immunother; 2008 Nov; 57(11):1635-45. PubMed ID: 18386000
[TBL] [Abstract][Full Text] [Related]
17. Antitumor IgE adjuvanticity: key role of Fc epsilon RI.
Nigro EA; Brini AT; Soprana E; Ambrosi A; Dombrowicz D; Siccardi AG; Vangelista L
J Immunol; 2009 Oct; 183(7):4530-6. PubMed ID: 19748979
[TBL] [Abstract][Full Text] [Related]
18. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients.
Victora GD; Socorro-Silva A; Volsi EC; Abdallah K; Lima FD; Smith RB; Moyses RA; Zárate-Bladés CR; Michaluart P; Silva CL; Kalil J; Coelho V
Cancer Gene Ther; 2009 Jul; 16(7):598-608. PubMed ID: 19197326
[TBL] [Abstract][Full Text] [Related]
19. An allogeneic hybrid-cell fusion vaccine against canine mammary cancer.
Bird RC; Deinnocentes P; Lenz S; Thacker EE; Curiel DT; Smith BF
Vet Immunol Immunopathol; 2008 Jun; 123(3-4):289-304. PubMed ID: 18423623
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy.
De Giovanni C; Nicoletti G; Landuzzi L; Croci S; Palladini A; Antognoli A; Murgo A; Ianzano ML; Grosso V; Stivani V; Iezzi M; Musiani P; Nanni P; Lollini PL
Vaccine; 2009 Mar; 27(14):2065-9. PubMed ID: 19428831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
